α-Galactosidase
- Generic Name
- α-Galactosidase
- Brand Names
- Fabrazyme
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- RZD65TSM9U
- Background
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta. Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamina...
- Indication
Agalsidase beta is indicated in the treatment of Fabry disease.
- Associated Conditions
- Fabry's Disease
- Associated Therapies
- -
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05698901
- Locations
- 🇨🇳
Charles Jia-Yin Hou, Taipei, Taiwan
China Post-marketing Surveillance (PMS) Study of Fabrazyme®
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 22
- Registration Number
- NCT05054387
- Locations
- 🇨🇳
Investigational Site Number :1560001, Shanghai, China
🇨🇳Investigational Site Number :1560006, Taiyuan, China
🇨🇳Investigational Site Number :1560005, Wuhan Shi, China
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
- Conditions
- Interventions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 7
- Registration Number
- NCT00230607
- Locations
- 🇦🇹
investigational site number 04Bodamer, Marl, Austria
🇬🇧investigational site number 03Waldek, Salford, United Kingdom
🇺🇸Investigational Site Number 840005, Decatur, Georgia, United States
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 6
- Registration Number
- NCT00140621
- Locations
- 🇯🇵
Fujita Health University Hospital, Aichi, Japan
🇯🇵Sapporo Medical University Hospital, Hokkaido, Japan
🇯🇵Tohoku University Hospital, Miyagi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.